Article
Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?
Pharmacogenomics - 1 Jul 2010
Ruaño Gualberto, Thompson Paul D, Kane John P, Pullinger Clive R, Windemuth Andreas, Seip Richard L, Kocherla Mohan, Holford Theodore R, Wu Alan H B
Abstract excerpt
AIM: Administered at maximal dosages, the most common statins--atorvastatin, simvastatin and rosuvastatin--lower low-density lipoprotein cholesterol (LDLC) by an average of 37-57% in patients with primary hypercholesterolemia. We hypothesized novel genetic underpinnings for variation in LDLC levels in the context of statin therapy. MATERIALS & METHODS: Genotyping of 384 SNPs in 202 volunteers from a lipid...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
